Event description
“Utilising Serological Markers to Predict Recurrent Plasmodium vivax Infections in the 'Patients Receiving Primaquine Radical Cure for Plasmodium falciparum (PRIMA)' Study” with Maulina Hafidzah
In areas where Plasmodium falciparum and Plasmodium vivax coexist, patients recovering from P. falciparum malaria remain at risk of P. vivax recurrence. The PRIMA study evaluates high-dose primaquine as a universal radical cure to prevent these recurrences. However, identifying who requires treatment remains a challenge. This presentation explores the potential of serological exposure markers (SEMs) to refine the PRIMA study by classifying P. vivax recurrence risk, enabling a more targeted approach to malaria treatment and elimination strategies.
Recordings will be available on the ACREME website.
Tickets for good, not greed Humanitix dedicates 100% of profits from booking fees to charity
